...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: ZEN-3694 Single Agent Trial Status
6
Oct 24, 2017 11:18AM
1
Oct 25, 2017 09:02AM
2
Oct 26, 2017 10:24AM
5
Oct 26, 2017 12:13PM

Nov 02, 2017 03:38PM

Nov 02, 2017 04:29PM

Nov 03, 2017 10:49AM

Nov 03, 2017 10:58AM

Nov 03, 2017 12:07PM
2
Nov 03, 2017 03:45PM
2
Nov 03, 2017 04:23PM
5
Nov 18, 2017 07:45PM

narmac - I hear you and agree however, having the ability to negotiate with a potential purchaser without your direct competitors knowing what their competition actually has is sometimes an advantage. I certainly hope this is the case. I was the one who brought this concern to the for after their  presentation last week when the chart on side 18 had not been updated from what we saw at the AGM, slide 17. For all we know there could be a bidding war going on between 2 or 3 companies at this time. The big challenge of course is that we just don't know and it's frustrating the heck out of some of us. I am definetly in that group.

tada

Share
New Message
Please login to post a reply